What is Non-invasive RhD testing?
![](https://diagnostics.medgenome.com/wp-content/uploads/2023/12/rhd1-scaled-1.jpg)
Non-invasive prenatal testing (NIPT) of fetal RhD status uses a real-time quantitative polymerase chain reaction (PCR) method to detect fetal RhD status using cell-free fetal DNA in RhD negative women. MedGenome brings this innovative non-invasive solution which enables that prophylaxis is administered only to those rhesus D-negative women who carry a D-positive fetus.
![](https://diagnostics.medgenome.com/wp-content/uploads/2023/12/rhd1-scaled-1.jpg)
Why RhD testing is required?
![](https://diagnostics.medgenome.com/wp-content/uploads/2023/12/rhd11-1-scaled-1.jpg)
- RhD negative pregnant women may carry a fetus with RhD positive blood group which may cause sensitisation, any time during the pregnancy, but it is most common in the third trimester and during childbirth.
- This itself has no adverse effects on the mother and does not usually affect the pregnancy during which it occurs.
- However, in a subsequent pregnancy with a RhD-positive fetus in women who have been sensitized to the RhD antigen, the woman’s anti-D antibodies may cross the placenta resulting in haemolytic disease of the fetus and new-born.
- Knowing the fetal RhD status helps decide management of each pregnancy, especially the need to administer prophylaxis with anti-RhD immunoglobulin to reduce the risk of the sensitisation in RhD-negative women and hence the prevalence of haemolytic disease of the fetus and new-born in subsequent pregnancies.
Who can benefit from NIPT Rhesus D Track?
![](https://diagnostics.medgenome.com/wp-content/uploads/2023/12/rhd22-1-scaled-1.jpg)
- Pregnant women with confirmed Rh-D negative status.
- Above gestational age of 11 weeks.
- Carrying a singleton pregnancy.
NIPT Rhesus D Track will benefit in early detection of Fetal RhD status to support Clinicians for better and effective management.
![](https://diagnostics.medgenome.com/wp-content/uploads/2023/12/Rhesus-D.png)
Test Sample Requirement for RhD
![](https://sp-ao.shortpixel.ai/client/q_glossy,ret_img/https://diagnostics.medgenome.com/wp-content/uploads/2019/08/test-sample02.png)
10 ml of maternal peripheral blood via an StreckTM tube.
Turn-around Time (TAT):
14 days
Free Genetic Counseling by MedGenome Genetic Experts
Please share your details with our genetic experts to answer your queries